Key result
α-Adrenoceptor antagonists have not been convincingly shown to be haemodynamically superior to drugs with less specific vasodilator activity in the treatment of hypertension and heart failure.
Why the study?
Are α-adrenoceptor antagonists hemodynamically superior to non-specific vasodilators in patients with hypertension and heart failure?
Population
Patients with hypertension and heart failure
Comparison
Vasodilators and α-adrenoceptor antagonists vs Non-specific vasodilators
Design
Review
Authors
Loading...
No hemodynamic superiority supports preferring α-adrenoceptor antagonists; leaves open their role versus non-specific vasodilators on clinical outcomes.
Are α-adrenoceptor antagonists hemodynamically superior to non-specific vasodilators in patients with hypertension and heart failure?
This review highlights that α-adrenoceptor antagonists do not offer clear hemodynamic superiority over non-specific vasodilators for managing hypertension and heart failure.
S. H. Taylor (1981) conducted a review in Hypertension and heart failure. Vasodilators and α-adrenoceptor antagonists was evaluated. α-Adrenoceptor antagonists have not been convincingly shown to be haemodynamically superior to drugs with less specific vasodilator activity in the treatment of hypertension and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: